Roundhill NVDA WeeklyPay ETF vs Zimmer Biomet Holdings Inc — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $36, while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while Roundhill NVDA WeeklyPay ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| NVDW | ZBH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $53.42 | $107.71 |
52-Week Low | $31.88 | $79.58 |
Market Cap | — | $17.36B |
Enterprise Value | — | $24.40B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
NVDW trades at $35.20, down 1.1% today, with technical indicators showing bearish momentum as moving averages signal strong selling pressure. The ETF maintains an active dividend distribution schedule with multiple payouts in recent months, though key valuation metrics remain unavailable for analysis. Current price action sits near support at $35 with resistance forming at $36.
The outlook remains cautious given the bearish technical signals and lack of fundamental data transparency. Investment opportunity exists primarily through the dividend income stream, though payout volatility presents risk. Market sentiment appears mixed with Seeking Alpha highlighting the ETF's role as a Nvidia hedge with variable yield characteristics.
No Aura AI signal available yet.
Trailing returns across standard periods
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →